BRIEF-GSK's Advair achieves primary endpoint in safety study of children
March 17, 2016 at 04:02 AM EDT
* Advair Diskus achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma Source text for Eikon: Further company coverage: (Reporting by UK bureau)
